← Back to Search

Pharmacotherapy

High-Intensity, Cancer-Targeted Smoking Cessation Treatment for Smoking Cessation

Phase 4

Waitlist Available

Led By Danielle E McCarthy, PhD

Research Sponsored by University of Wisconsin, Madison

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosed with cancer in the past 3 years

No flag for patient cognitive impairment, activated health care power of attorney, or other health care agent (e.g., legally authorized representative) in the EHR

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 30 weeks post target quit date

Awards & highlights

Study Summary

This trial will compare two different ways to help cancer patients quit smoking. One group will receive 12 weeks of varenicline treatment and coaching calls focused on quitting smoking with cancer. The other group

Who is the study for?

This trial is for adult cancer patients who were diagnosed within the last 3 years and are looking to quit smoking. It's not specified who can't join, but typically those with health conditions that may interfere with the treatment or assessment might be excluded.Check my eligibility

What is being tested?

The study compares two smoking cessation methods: an enhanced treatment with varenicline pills and targeted coaching calls, versus a standard approach using nicotine patches and regular phone counseling. The goal is to see which method helps more people quit smoking after 26 weeks.See study design

What are the potential side effects?

Varenicline may cause nausea, sleep problems, constipation, gas, or vomiting. Nicotine patches can lead to skin irritation at the patch site, dizziness, racing heartbeat or headaches.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I was diagnosed with cancer within the last 3 years.

Select...

I do not have a cognitive impairment and do not have a health care power of attorney.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 30 weeks post target quit date

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 30 weeks post target quit date

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 weeks post target quit date for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Biochemically verified 7-day point-prevalence abstinence 26 weeks after a target quit date.

Secondary outcome measures

Self-reported 7-day point-prevalence abstinence 12 weeks after a target quit date.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: High-Intensity, Cancer-Targeted Smoking Cessation TreatmentExperimental Treatment3 Interventions

12 weeks of varenicline therapy, 7 counseling sessions targeted to cancer patients, and information about quitline and SmokefreeTXT services

Group II: Low-Intensity Standard Smoking Cessation TreatmentActive Control3 Interventions

2 weeks of nicotine patch therapy, 3 telephone counseling sessions, and information about quitline and National Cancer Institute text messaging support services (SmokefreeTXT)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Varenicline

2011

Completed Phase 4

~4170

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,658 Previous Clinical Trials

40,924,439 Total Patients Enrolled

University of Wisconsin, MadisonLead Sponsor

1,183 Previous Clinical Trials

3,167,537 Total Patients Enrolled

Danielle E McCarthy, PhDPrincipal InvestigatorUniversity of Wisconsin, Madison

1 Previous Clinical Trials

13,000 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this medical trial currently accepting new participants?

"According to the information provided by clinicaltrials.gov, this particular trial is not actively seeking participants at the moment. The trial was first posted on January 1st, 2024 and last updated on January 12th, 2024. However, there are currently 660 other studies available for enrollment if you are interested in participating in a different clinical trial."

Answered by AI

What are the potential risks associated with the High-Intensity, Cancer-Targeted Smoking Cessation Treatment for individuals?

"Based on our assessment at Power, the safety rating for High-Intensity, Cancer-Targeted Smoking cessation Treatment is 3. This determination stems from it being a Phase 4 trial and evidence of its approval as a treatment option."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Tobacco Treatment Comparison for Cancer Care

2024. "Tobacco Treatment Comparison for Cancer Care". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06218823.

All > Chantix